American Home Products obtains FDA approval

AHP received FDA approval for its Mylotarg gemtuzumab ozogamicin injection to treat patients 60 years and older in first relapse with CD33-positive acute myleloid leukemia (AML) who are not candidates for cytotoxic chemotherapy. Mylotarg will be marketed by Wyeth-Ayerst Laboratories (Philadelphia, Penn.), the pharmaceutical division of AHP. Mylotarg, a humanized antibody linked to calicheamicin, was developed jointly by Wyeth-Ayerst and Celltech (LSE:CCH; CLL). ...